Aperio Group LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 397,207 shares of the medical research company’s stock after purchasing an additional 4,078 shares during the quarter. Aperio Group LLC owned about 0.10% of Thermo Fisher Scientific worth $96,950,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its holdings in shares of Thermo Fisher Scientific by 3.2% in the second quarter. Dimensional Fund Advisors LP now owns 2,670,961 shares of the medical research company’s stock valued at $553,246,000 after purchasing an additional 82,255 shares during the period. Brown Advisory Inc. grew its holdings in shares of Thermo Fisher Scientific by 2.4% in the first quarter. Brown Advisory Inc. now owns 2,144,864 shares of the medical research company’s stock valued at $442,830,000 after purchasing an additional 49,320 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Thermo Fisher Scientific by 1.7% in the second quarter. Janus Henderson Group PLC now owns 2,036,659 shares of the medical research company’s stock valued at $421,880,000 after purchasing an additional 34,401 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of Thermo Fisher Scientific by 3.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 1,566,563 shares of the medical research company’s stock valued at $324,498,000 after purchasing an additional 46,519 shares during the period. Finally, Findlay Park Partners LLP grew its holdings in shares of Thermo Fisher Scientific by 8.9% in the second quarter. Findlay Park Partners LLP now owns 1,525,000 shares of the medical research company’s stock valued at $315,889,000 after purchasing an additional 125,000 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.

NYSE TMO opened at $234.65 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $181.51 and a 12 month high of $249.95. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.11 and a current ratio of 1.58. The stock has a market capitalization of $98.31 billion, a price-to-earnings ratio of 24.73, a P/E/G ratio of 1.78 and a beta of 1.12.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 25th. The medical research company reported $2.75 EPS for the quarter, beating the Zacks’ consensus estimate of $2.63 by $0.12. Thermo Fisher Scientific had a net margin of 10.36% and a return on equity of 16.28%. The company had revenue of $6.08 billion for the quarter, compared to analysts’ expectations of $5.90 billion. During the same quarter in the prior year, the company posted $2.30 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 21.8% compared to the same quarter last year. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 10.98 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase program on Friday, September 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 2.1% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

A number of brokerages recently issued reports on TMO. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $242.00 to $254.00 and gave the company an “overweight” rating in a report on Wednesday, October 10th. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a research report on Tuesday, July 24th. Citigroup upped their target price on shares of Thermo Fisher Scientific from $260.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, October 10th. Leerink Swann upped their target price on shares of Thermo Fisher Scientific from $239.00 to $255.00 and gave the company an “outperform” rating in a research report on Thursday, July 26th. Finally, ValuEngine cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, June 20th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $259.91.

In other news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Monday, August 6th. The shares were sold at an average price of $233.95, for a total transaction of $11,697,500.00. Following the sale, the chief executive officer now owns 320,122 shares of the company’s stock, valued at $74,892,541.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 125,520 shares of the stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $247.50, for a total transaction of $31,066,200.00. The disclosure for this sale can be found here. Insiders have sold 196,070 shares of company stock worth $47,569,729 in the last three months. Corporate insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: Growth Stocks, What They Are, What They Are Not

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.